within Pharmacolibrary.Drugs.ATC.A;

model A10AC04_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.8333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.03,
    k12             = 4,
    k21             = 4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10AC04_1</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Insulin lispro is a rapid-acting human insulin analog used for glycemic control in diabetes mellitus. It acts quickly to lower blood glucose and is approved for medical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for adult patients with type 1 diabetes after subcutaneous injection.</p><h4>References</h4><ol><li><p>Grant, M, et al., &amp; Baughman, R (2022). Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus. <i>Clinical pharmacokinetics</i> 61(3) 413–422. DOI:<a href=\"https://doi.org/10.1007/s40262-021-01084-0\">10.1007/s40262-021-01084-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34773608/\">https://pubmed.ncbi.nlm.nih.gov/34773608</a></p></li><li><p>Garhyan, P, et al., &amp; Dassau, E (2023). Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes. <i>Journal of diabetes science and technology</i> 17(2) 274–282. DOI:<a href=\"https://doi.org/10.1177/19322968221145200\">10.1177/19322968221145200</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36575993/\">https://pubmed.ncbi.nlm.nih.gov/36575993</a></p></li><li><p>Caparrotta, TM, &amp; Evans, M (2014). PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue. <i>Diabetes, obesity &amp; metabolism</i> 16(5) 388–395. DOI:<a href=\"https://doi.org/10.1111/dom.12196\">10.1111/dom.12196</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23941279/\">https://pubmed.ncbi.nlm.nih.gov/23941279</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10AC04_1;
